Specific binding protein and application thereof

A composition and monoclonal antibody technology, applied in the medical field, can solve problems such as low EGFRvIII specificity and unsatisfactory antibodies
CN101602808AActive Publication Date: 2009-12-16SHANGHAI INST OF ONCOLOGY
0 Cites 32 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
SHANGHAI INST OF ONCOLOGY
Publication Date
2009-12-16

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a specific binding protein and an application thereof and particularly provides a monoclonal antibody which can be effectively bound with an epidermal growth factor receptor mutant III (EGFRv III) or partially bound with an epidermal growth factor receptor (EGFR) with overexpressed cells, but has no binding effect with an EGFR with normally expressed cells. In addition, the monoclonal antibody has obvious therapeutic effect on a tumor cell line which expresses the EGFRv III. The invention also provides a method for preparing the monoclonal antibody and a medical composition containing the monoclonal antibody.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of medicine. More specifically, the present invention relates to specific monoclonal antibodies against epidermal growth factor receptor mutant III (EGFRvIII) and applications thereof. The antibody of the present invention can effectively bind to EGFRvIII or partially bind to epidermal growth factor receptor (EGFR) overexpressed by cells, and the antibody has no binding effect on EGFR normally expressed by cells. The antibodies of the invention can be used to treat tumor cell lines expressing EGFRvIII. Background technique

[0002] Epidermal growth factor receptor (EGFR) is the 170 kilodalton membrane glycoprotein product of the proto-oncogene c-erb B (1) . The EGFR gene is the cellular homologue of the erb B oncogene originally identified in avian erythrocytosis virus (1，2) . Activation of this oncogene by gene amplification has been observed in various human tumors (3-6) .

[0003] It has been shown i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More